Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
The current Neurocrine(NBIX) stock price is $143.02, with a market capitalization of 14.26B. The stock trades at a price-to-earnings (P/E) ratio of 33.84.
On 2025-12-18, Neurocrine(NBIX) stock traded between a low of $141.23 and a high of $143.52. Shares are currently priced at $143.02, which is +1.3% above the low and -0.3% below the high.
The Neurocrine(NBIX)'s current trading volume is 456.12K, compared to an average daily volume of 1.02M.
During the past year, Neurocrine(NBIX) stock moved between $84.23 at its lowest and $160.18 at its peak.
During the past year, Neurocrine(NBIX) stock moved between $84.23 at its lowest and $160.18 at its peak.
NBIX News
Neurocrine Biosciences (NBIX) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund...
H.C. Wainwright raised the firm’s price target on Neurocrine (NBIX) to $198 from $168 and keeps a Buy rating on the shares following the research and developmen...
Analyst Ami Fadia from Needham maintained a Buy rating on Neurocrine and keeping the price target at $184.00. Claim 50% Off TipRanks Premium and Invest with Con...
Analyst ratings
90%
of 30 ratingsMore NBIX News
In a report released yesterday, Yigal Nochomovitz from Citi maintained a Buy rating on Neurocrine, with a price target of $203.00. Claim 50% Off TipRanks Premiu...
Neurocrine Biosciences (NBIX) has quietly kept shareholders rewarded this year, with the stock up about 11% year to date and roughly 21% over the past year desp...
